W P Fay

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi request reprint High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi
    W P Fay
    Department of Internal Medicine Cardiology, University of Michigan Medical School, Ann Arbor, USA
    Arterioscler Thromb Vasc Biol 16:1277-84. 1996
  2. ncbi request reprint Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury
    William P Fay
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Trends Cardiovasc Med 14:196-202. 2004
  3. ncbi request reprint Vitronectin inhibits the thrombotic response to arterial injury in mice
    W P Fay
    Departments of Internal Medicine and Human Genetics and the Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI, USA
    Blood 93:1825-30. 1999
  4. ncbi request reprint Effects of radiographic contrast agents on thrombin formation and activity
    W P Fay
    Department of Internal Medicine Cardiology, University of Michigan Medical School, and the Ann Arbor Veterans Affairs Hospital, USA
    Thromb Haemost 80:266-72. 1998
  5. ncbi request reprint Functional analysis of the amino- and carboxyl-termini of streptokinase
    W P Fay
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor Veterans Affairs Hospital, USA
    Thromb Haemost 79:985-91. 1998
  6. ncbi request reprint An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents
    P M Farrehi
    Department of Internal Medicine (Cardiology, University of Michigan Medical School, Ann Arbor, MI 48109-0644, USA
    J Thromb Thrombolysis 12:273-81. 2001
  7. ncbi request reprint Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice
    Y Zhu
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USA
    Circulation 103:3105-10. 2001
  8. ncbi request reprint Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance
    Y Zhu
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Circulation 99:3050-5. 1999
  9. pmc Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices
    N Garg
    Department of Internal Medicine, University of Missouri School of Medicine and Research Service, Harry S Truman Memorial Veterans Affairs Hospital, Columbia, MO, USA
    J Thromb Haemost 8:1847-54. 2010
  10. ncbi request reprint Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall
    Sharlene M Day
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Blood 105:192-8. 2005

Collaborators

Detail Information

Publications30

  1. ncbi request reprint High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi
    W P Fay
    Department of Internal Medicine Cardiology, University of Michigan Medical School, Ann Arbor, USA
    Arterioscler Thromb Vasc Biol 16:1277-84. 1996
    ..These studies also underscore the importance of considering possible species differences in protein function when comparing animal models of thrombosis to acute coronary thrombosis in humans...
  2. ncbi request reprint Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury
    William P Fay
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Trends Cardiovasc Med 14:196-202. 2004
    ..This review examines recent studies addressing the vascular function of PAI-1, and those assessing the role of fibrin as a downstream mediator of PAI-1's effects...
  3. ncbi request reprint Vitronectin inhibits the thrombotic response to arterial injury in mice
    W P Fay
    Departments of Internal Medicine and Human Genetics and the Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI, USA
    Blood 93:1825-30. 1999
    ....
  4. ncbi request reprint Effects of radiographic contrast agents on thrombin formation and activity
    W P Fay
    Department of Internal Medicine Cardiology, University of Michigan Medical School, and the Ann Arbor Veterans Affairs Hospital, USA
    Thromb Haemost 80:266-72. 1998
    ..These findings may help to explain the reduced risk of thrombosis during coronary angioplasty associated with ionic contrast agents...
  5. ncbi request reprint Functional analysis of the amino- and carboxyl-termini of streptokinase
    W P Fay
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor Veterans Affairs Hospital, USA
    Thromb Haemost 79:985-91. 1998
    ..These results also suggest that SK fragments significantly smaller than SK 13-374 are unlikely to be effective thrombolytic agents...
  6. ncbi request reprint An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents
    P M Farrehi
    Department of Internal Medicine (Cardiology, University of Michigan Medical School, Ann Arbor, MI 48109-0644, USA
    J Thromb Thrombolysis 12:273-81. 2001
    ..Significant variation in antifibrinolytic properties exists between different contrast agents...
  7. ncbi request reprint Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice
    Y Zhu
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USA
    Circulation 103:3105-10. 2001
    ..Alternatively, hyperlipidemia may alter the pattern of gene expression in the blood vessel wall to enhance potential effects of PAI-1 on antiproliferative processes, such as transforming growth factor-beta activation and apoptosis...
  8. ncbi request reprint Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance
    Y Zhu
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Circulation 99:3050-5. 1999
    ..We used a murine carotid injury model to test the hypothesis that PAI-1 inhibits thrombolysis mediated by pharmacological concentrations of tPA...
  9. pmc Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices
    N Garg
    Department of Internal Medicine, University of Missouri School of Medicine and Research Service, Harry S Truman Memorial Veterans Affairs Hospital, Columbia, MO, USA
    J Thromb Haemost 8:1847-54. 2010
    ..Vascular smooth muscle cell (VSMC) migration is a critical process in arterial remodeling. Purified plasminogen activator inhibitor-1 (PAI-1) is reported to both promote and inhibit VSMC migration on two-dimensional (D) surfaces...
  10. ncbi request reprint Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall
    Sharlene M Day
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Blood 105:192-8. 2005
    ..Therefore, our results suggest that thrombus formation in the arterial and venous macrovasculature is driven primarily by TF derived from the blood vessel wall as opposed to leukocytes...
  11. doi request reprint C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance
    Jianbo Wu
    Department of Internal Medicine, University of Missouri School of Medicine, and Research Service, Harry S Truman Memorial Veterans Affairs Hospital, Columbia, MO 65212, USA
    Arterioscler Thromb Vasc Biol 28:698-704. 2008
    ..We examined the impact of C-reactive protein (CRP) on vascular smooth muscle cell (VSMC) expression of tissue factor (TF) and TF pathway inhibitor (TFPI)...
  12. ncbi request reprint Myocardial proinflammatory cytokine expression and left ventricular remodeling in patients with chronic mitral regurgitation
    Hakan Oral
    Division of Cardiology, University of Michigan and Veterans Affairs Medical Centers, Ann Arbor, USA
    Circulation 107:831-7. 2003
    ....
  13. ncbi request reprint Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis
    Sharlene M Day
    University of Michigan Medical School, Division of Cardiology, Ann Arbor, USA
    Circulation 107:2601-6. 2003
    ..Iron overload has been implicated in the pathogenesis of ischemic cardiovascular events. However, the effects of iron excess on vascular function and the thrombotic response to vascular injury are not well understood...
  14. ncbi request reprint Vascular functions of the plasminogen activation system
    William P Fay
    Department of Internal Medicine, University of Missouri School of Medicine, Columbia, MO 65212, USA
    Arterioscler Thromb Vasc Biol 27:1231-7. 2007
    ..Lastly, the strengths and limitations of using mice to model human vascular disease processes are discussed...
  15. ncbi request reprint Do clinically relevant circulating concentrations of radiographic contrast agents inhibit platelet-dependent arterial thrombosis?
    Yanhong Zhu
    Department of Internal Medicine Cardiology, University of Michigan Medical School, and the Ann Arbor Veterans Affairs Hospital, Ann Arbor, MI, USA
    Thromb Res 105:413-8. 2002
    ..The purpose of this study was to determine if radiographic contrast agents (RCAs) inhibit thrombosis in a rat carotid artery injury model...
  16. ncbi request reprint Plasminogen is a critical host pathogenicity factor for group A streptococcal infection
    Hongmin Sun
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
    Science 305:1283-6. 2004
    ..In addition, local fibrin clot formation may be implicated in host defense against microbial pathogens...
  17. pmc Recombinant plasminogen activator inhibitor-1 inhibits intimal hyperplasia
    Jianbo Wu
    Department of Internal Medicine, University of Missouri School of Medicine, and Research Service, Harry S Truman Memorial Veterans Affairs Hospital, Columbia, MO 65212, USA
    Arterioscler Thromb Vasc Biol 29:1565-70. 2009
    ..However, the effects of a primary increase in PAI-1 expression on arterial remodeling are poorly defined. We tested the hypothesis that recombinant PAI-1 inhibits intimal hyperplasia after vascular injury...
  18. ncbi request reprint Murine thrombosis models
    Sharlene M Day
    Department of Internal Medicine, University of Michigan Medical Center, 7301 MSRB III, 1150 W Medical Center Drive, Ann Arbor, Michigan 48109 0644, USA
    Thromb Haemost 92:486-94. 2004
    ..The advantages and limitations of different models are examined. Related topics of mouse anesthesia, phlebotomy, and in vitro hemostasis testing are also reviewed...
  19. ncbi request reprint Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries
    Lin Peng
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USA
    Arterioscler Thromb Vasc Biol 22:934-9. 2002
    ..Their effects may be mediated to a significant extent by their capacity to promote intravascular fibrin deposition and by the capacity of vitronectin to enhance VSMC-fibrin interactions...
  20. ncbi request reprint Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene
    W P Fay
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, USA
    Blood 90:204-8. 1997
    ..These observations define the clinical spectrum of PAI-1 deficiency and provide additional evidence to support the hypothesis that the primary function of plasminogen activator inhibitor-1 in vivo is to regulate vascular fibrinolysis...
  21. ncbi request reprint Factor VLeiden inhibits fibrinolysis in vivo
    Andrew C Parker
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor 48109 0644, USA
    Circulation 110:3594-8. 2004
    ..Factor V(Leiden) (fV(Leiden)) predisposes to thrombosis by enhancing thrombin formation. This study tested the hypothesis that fV(Leiden) inhibits fibrinolysis in vivo...
  22. ncbi request reprint Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin
    Abrar Ahmed
    Department of Internal Medicine, School of Medicine, University of Missouri Columbia, MA406, DC043 00, One Hospital Drive, Columbia, MO 65212, USA
    J Thromb Thrombolysis 26:44-8. 2008
    ..the conventional strategy of not changing warfarin dose and carefully following international normalized ratio (INR) results...
  23. ncbi request reprint Plasminogen activator inhibitor-1 and restenosis
    Nadish Garg
    Department of Internal Medicine, University of Missouri School of Medicine, Columbia, MO, USA
    Curr Drug Targets 8:1003-6. 2007
    ..In this review we examine the role of plasminogen activator inhibitor-1 (PAI-1) in controlling restenosis after balloon angioplasty and stent implantation...
  24. ncbi request reprint The duration of anticoagulation bridging therapy in clinical practice may significantly exceed that observed in clinical trials
    Jacob P Deerhake
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    J Thromb Thrombolysis 23:107-13. 2007
    ..The purpose of this study was to determine if the anticoagulation results of clinical trials of LMWH bridging therapy are also achieved in a single-center clinical practice setting...
  25. ncbi request reprint Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice
    Haim D Danenberg
    Harvard MIT Division of Health Sciences and Technology, Cambridge, Mass 02139, USA
    Circulation 108:512-5. 2003
    ..To determine whether CRP directly modulates vascular cell function in vivo, we subjected wild-type mice, which do not express CRP, and human CRP-transgenic (CRPtg) mice to 2 models of arterial injury...
  26. pmc Double knockouts reveal that protein tyrosine phosphatase 1B is a physiological target of calpain-1 in platelets
    Shafi M Kuchay
    Department of Pharmacology, UIC Cancer Center, University of Illinois at Chicago, 909 South Wolcott Avenue, Room 5097, Chicago, IL 60612 3725, USA
    Mol Cell Biol 27:6038-52. 2007
    ..Together, our results demonstrate that PTP1B is a physiological target of calpain-1 and suggest that a similar mechanism may regulate calpain-1-mediated tyrosine dephosphorylation in other cells...
  27. ncbi request reprint Atherosclerosis in mice is not affected by a reduction in tissue factor expression
    Rachel E Tilley
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    Arterioscler Thromb Vasc Biol 26:555-62. 2006
    ..To determine whether tissue factor (TF) contributes to the progression of atherosclerotic lesions in mice...
  28. ncbi request reprint Induction of heme oxygenase-1 expression inhibits platelet-dependent thrombosis
    Lin Peng
    Antioxid Redox Signal 6:729-35. 2004
    ..Enhanced HO-1 expression in response to oxidative stress may represent an adaptive response mechanism to down-regulate platelet activation under prothrombotic conditions...
  29. pmc Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life
    Mariko Nagashima
    Department of Cardiovascular Research, Berlex Biosciences, Richmond, California 94804, USA
    J Clin Invest 109:101-10. 2002
    ..The current study demonstrates that TAFI deficiency does not change normal responses to acute challenges...
  30. ncbi request reprint Antidote-mediated control of an anticoagulant aptamer in vivo
    Christopher P Rusconi
    Department of Surgery, Center for Translational Research, Duke University Medical Center, Campus Box 2601, Durham, North Carolina 27710, USA
    Nat Biotechnol 22:1423-8. 2004
    ..These results demonstrate that rationally designed drug-antidote pairs can be generated to provide control over drug activities in animals...